Spago Nanomedical: Next dose evaluation approaching – Q2 review
Börskollen - Aktier, fonder och ekonominyheter
BörskollenFör dig med koll på börsen
•Jämförelse: Hitta Sveriges bästa passiva spartjänst – stor granskning av 5 alternativ

Pressmeddelande

Spago Nanomedical: Next dose evaluation approaching – Q2 review

MFN Publicerad: 20 Aug 16:30

DNB Carnegie has published a new commissioned research report on Spago Nanomedical.

To access the full report and subscribe to future updates, visit https://www.carnegie.se/en/commissioned-research/spago/

Information
This is a press release from DNB Carnegie. For information about DNB Carnegie commissioned research, see https://www.carnegie.se/en/commissioned-research/, or contact our commissioned research team at [email protected].

About Us
DNB Carnegie is the leading and independent Nordic investment and private bank. Our operations within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together, they build an unbeatable combination of integrated knowledge, guiding our clients towards better business. DNB Carnegie operates in six countries and has more than 800 employees.

Läses av andra just nu

Senaste nytt